cannabidiol/dronabinol (GWP42002/GWP42003) / Jazz - LARVOL DELTA

Epidiolex and Drug Resistant Epilepsy in Children (clinicaltrials.gov) - P=N/A; N=N/A; Available; Sponsor: Georgia Regents University

New trial • Biosimilar • Epilepsy

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (clinicaltrials.gov) - P3; N=120; Active, not recruiting; Sponsor: GW Research Ltd; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Epilepsy

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (clinicaltrials.gov) - P3; N=80; Active, not recruiting; Sponsor: GW Research Ltd; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Epilepsy

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: University of Colorado, Denver

New P2 trial • Alzheimer's Disease • Biosimilar • Gene Therapies • Parkinson's Disease

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (clinicaltrials.gov) - P2; N=30; Active, not recruiting; Sponsor: GW Research Ltd; Trial primary completion date: Mar 2015 ->Jul 2015

Trial primary completion date • Biosimilar • Epilepsy

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Central Institute of Mental Health, Mannheim; Trial completion date: May 2020 ➔ May 2022; Trial primary completion date: Apr 2020 ➔ Apr 2022

Trial completion date • Trial primary completion date